LEADER 00801nam0-22002891i-450-
001 990003095660403321
035   $a000309566
035   $aFED01000309566
035   $a(Aleph)000309566FED01
035   $a000309566
100   $a20000920d1995----km-y0itay50------ba
101 0 $aeng
102   $aIT
200 1 $aImplementing the Strategy$fOECD.
210   $aParis$cOECD$d1995.
215   $a32 p.$d30 cm
225 1 $a<<The >>OECD Jobs Study
610 0 $aDisoccupazione$aPaesi OCSE
676   $aG/2.12
710  2$aOrganizzazione per la cooperazione e lo sviluppo economico$0493271
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990003095660403321
952   $aA/6.0 OECD/95$b16103$fSES
959   $aSES
996   $aImplementing the Strategy$9459716
997   $aUNINA

LEADER 01275nam2-2200409---450-
001 990001782730203316
005 20070403113705.0
035   $a000178273
035   $aUSA01000178273
035   $a(ALEPH)000178273USA01
035   $a000178273
100   $a20040623d1988----km-y0itay0103----ba
101 0 $aita
102   $aIT
105   $aa|||||||001yy
200 1 $a<<vol. 2.>> : Purgatorio$fGiovanni Marchese, Salvatore Rossi
210   $aPalermo$cPalumbo$d1988
215   $a202 p.$cill.$d23 cm
225 2 $aLettura dei capolavori$v4
410  0$12001$aLettura dei capolavori$v4
454  1$12001
461  1$10010081902$12001$aGuida alla lettura de la Divina Commedia
604 0 $aAlighieri, Dante$xDivina Commedia$xCritica del Testo
676   $a851.1
700  1$aMARCHESE,$bGiovanni$0334162
701  1$aROSSI,$bSalvatore$083265
801  0$aIT$bsalbc$gISBD
912   $a990001782730203316
951   $aVI.2.B. 251/2(V A Coll. 177/4)$b95612 L.M.$cV A Coll.
959   $aBK
969   $aUMA
979   $aSIAV1$b10$c20040623$lUSA01$h0914
979   $aCOPAT7$b90$c20060223$lUSA01$h1056
979   $aCOPAT7$b90$c20060223$lUSA01$h1056
979   $aCOPAT7$b90$c20070403$lUSA01$h1137
996   $aPurgatorio$9952625
997   $aUNISA

LEADER 01790oam  2200493   450 
001 9910715017103321
005 20210402093054.0
035   $a(CKB)5470000002507836
035   $a(OCoLC)1224541481$z(OCoLC)1227256921
035   $a(EXLCZ)995470000002507836
100   $a20201130d2020      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aFairness in Orphan Drug Exclusivity Act $ereport (to accompany H.R. 4712)
210  1$a[Washington, D.C.] :$c[U.S. Government Publishing Office],$d[2020]
215   $a1 online resource (11 pages)
225 1 $aReport / 116th Congress, 2d session, House of Representatives ;$v116-572
300   $a"November 16, 2020."
320   $aIncludes bibliographical references.
517   $aFairness in Orphan Drug Exclusivity Act 
606   $aDrug development$xEconomic aspects$zUnited States
606   $aBuprenorphine$xTherapeutic use$zUnited States
606   $aOrphan drugs$xGovernment policy$zUnited States
606   $aDrugs$xPrices$xGovernment policy$zUnited States
606   $aDrugs$xLaw and legislation$zUnited States
606   $aOrphan drugs$zUnited States
606   $aRare diseases$zUnited States
608   $aLegislative materials.$2lcgft
615  0$aDrug development$xEconomic aspects
615  0$aBuprenorphine$xTherapeutic use
615  0$aOrphan drugs$xGovernment policy
615  0$aDrugs$xPrices$xGovernment policy
615  0$aDrugs$xLaw and legislation
615  0$aOrphan drugs
615  0$aRare diseases
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910715017103321
996   $aFairness in Orphan Drug Exclusivity Act$93527578
997   $aUNINA